Personalized Melanoma Vaccine Shows Strong Phase 3 Results

  • Early data from the INTerpath‑001 phase 3 trial show that an individualized mRNA vaccine combined with Keytruda may significantly reduce recurrence and distant spread in high‑risk, resected melanoma.
  • Experts say the approach represents a major advance in adjuvant therapy, with Dr. Jeff Ishizuka at Yale School of Medicine calling it “a true breakthrough” in patient‑specific cancer vaccination.
  • The approval applies only to high‑risk, resectable stage IIB–IV melanoma, not unresectable stage IV or clinical stage III disease; Dr. Ankit Mangla at UH Seidman Cancer Center stresses this distinction, noting the regimen is “not intended for patients who present with stage IV melanoma.”
  • The vaccine–immunotherapy combination met key endpoints for recurrence‑free and distant metastasis‑free survival, building on earlier phase 2b results that showed a 49% reduction in recurrence or death and a 59% reduction in distant metastasis or death compared with Keytruda alone.

Emerging trial results from an investigational personalized mRNA vaccine point to substantial promise in adjuvant melanoma therapy, a disease with a well‑recognized propensity for recurrence and distant spread despite complete surgical resection.

The early trial results suggest this vaccine approach may reduce the likelihood of disease returning or progressing in patients at elevated risk.

“Cancer vaccines have always seemed to hold great promise, but the field has met several challenges, including drugs that looked great in earlier trials but failed this step. Success at this level using this type of patient-specific mRNA vaccine represents a true breakthrough,” Dr. Jeff Ishizuka, a medical oncologist at Yale School of Medicine, tells SurvivorNet.

A phase 3 clinical trial, INTerpath-001, evaluated personalized vaccine intismeran autogene (also known as V940 or mRNA-4157). The vaccine, developed by Moderna and Merck, was given after surgery in combination with the immunotherapy drug pembrolizumab (brand name: Keytruda) in patients who were considered high-risk of having their melanoma return.

Dr. Ankit Mangla, Co‑Director of the Sarcoma & Cutaneous Oncology Team at UH Seidman Cancer Center, says the Phase 3 INTERPATH‑001 results are highly encouraging for Merck and Moderna as they seek full FDA approval, but emphasizes that the therapy is still far from routine clinical adoption.

“This approval is in the adjuvant setting for patients with high-risk resectable melanoma (Stage IIB to resected stage IV), which means it is not intended for patients who present with stage 4 melanoma or those who progress to stage IV and are deemed unresectable. These results are also not applicable to patients who present with clinical stage III melanoma, for whom neoadjuvant immunotherapy is the pathway,” Dr. Mangla explained.

He notes that the approval applies strictly to the adjuvant setting for patients with high‑risk, resectable melanoma (stage IIB through resected stage IV). It is not intended for patients who present with stage IV disease or progress to unresectable stage IV, and the findings do not apply to clinical stage III melanoma, where neoadjuvant immunotherapy remains the standard approach.

The trial enrolled patients with completely resected (fully removed through surgery) stage IIB–IV melanoma and tested the combination as adjuvant therapy, an additional treatment given after surgery in an attempt to keep cancer under control for longer.

The study met its primary endpoint of recurrence‑free survival (RFS) and a key secondary endpoint of distant metastasis‑free survival (DMFS), which means how long a patient lives without the cancer spreading.

“If these data are superior to data for single-agent PD-1 inhibitors in the adjuvant setting and safety data are reasonable, this could be a new standard of care,” Dr. Leslie Anne Fecher, a Clinical Professor of Internal Medicine (Hematology/Oncology) and Dermatology at the University of Michigan Medical School, tells SurvivorNetConnect.

How Could a Melanoma Vaccine Change the Standard Approach to Care?

Dr. Ahmad Tarhini, a medical oncologist at Moffitt Cancer Center, says, “If this immunotherapy regimen is granted FDA approval, it is expected to become a frontline treatment option. Therefore, melanoma specialists will be discussing intismeran plus Keytruda with all eligible patients.”

Moderna notes this is the first positive phase 3 result for an individualized neoantigen therapy and an mRNA‑based cancer treatment. It’s also the first phase 3 trial to show a meaningful improvement over Keytruda alone in the adjuvant melanoma setting. A neoantigen therapy is a type of personalized cancer treatment designed to train the immune system to recognize and attack a patient’s specific tumor.

It’s important to note that the full data have not yet been released. Moderna and Merck say they plan to present detailed trial results at an upcoming international medical meeting.

Dr. Douglas Johnson, clinical director of melanoma at Vanderbilt-Ingram Cancer Center, tells SurvivorNet this regimen could become a new standard of care for patients with high-risk stage II to IV melanoma, “a large population that needs more effective treatment options.”

“It is also possible, depending on the magnitude of benefit, that it could reignite the debate about whether adjuvant vs neoadjuvant therapy is more effective in certain patients with stage III melanoma,” Dr. Johnson adds.

For practicing physicians, Dr. Raman Madan, chief of dermatology at Northwell Health, believes this regimen “could make tumor sequencing and obtaining adequate tissue increasingly important early in the treatment process because the vaccine is individualized to each patient’s tumor. Specialists will also need to weigh the added benefit against manufacturing time, toxicity, cost, and an individual patient’s recurrence risk.”

As Merck Research Laboratories President Dr. Dean Y. Li explains, the goal of adjuvant therapy after surgery is to increase the chance of cure for more patients.

The latest phase 3 findings build on promising results from a smaller, phase 2b study, KEYNOTE‑942/mRNA‑4157‑P201, which included five‑year follow‑up data and was presented at the 2026 ASCO Annual Meeting.

In that study, the vaccine + immunotherapy combination:

  • Reduced the risk of recurrence or death by 49%
  • Reduced the risk of distant metastasis or death by 59% compared with Keytruda alone

“Given that this phase 3 study, INTerpath-001, appears to confirm prior promising data from a smaller study (KEYNOTE-942), there is a high chance that intismeran plus Keytruda will change the adjuvant melanoma treatment standard of care,” Dr. Tarhini tells SurvivorNet.